These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 1913520

  • 1. Coordinate elevation of serum markers in ovarian cancer but not in benign disease.
    Bast RC, Knauf S, Epenetos A, Dhokia B, Daly L, Tanner M, Soper J, Creasman W, Gall S, Knapp RC.
    Cancer; 1991 Oct 15; 68(8):1758-63. PubMed ID: 1913520
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase, in patients with ovarian carcinoma, borderline tumors, or benign adnexal masses: relevance for differential diagnosis.
    Tholander B, Taube A, Lindgren A, Sjöberg O, Stendahl U, Kiviranta A, Hallman K, Holm L, Weiner E, Tamsen L.
    Gynecol Oncol; 1990 Oct 15; 39(1):16-25. PubMed ID: 2227569
    [Abstract] [Full Text] [Related]

  • 4. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3.
    Jacobs IJ, Oram DH, Bast RC.
    Obstet Gynecol; 1992 Sep 15; 80(3 Pt 1):396-9. PubMed ID: 1495694
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal.
    van Haaften-Day C, Shen Y, Xu F, Yu Y, Berchuck A, Havrilesky LJ, de Bruijn HW, van der Zee AG, Bast RC, Hacker NF.
    Cancer; 2001 Dec 01; 92(11):2837-44. PubMed ID: 11753957
    [Abstract] [Full Text] [Related]

  • 7. Tumor antigen NB/70K and CA 125 levels in the blood of preoperative ovarian cancer patients and controls: a preliminary report of the use of the NB12123 and CA 125 radioimmunoassays alone and in combination.
    Knauf S, Bast RC.
    Int J Biol Markers; 1988 Dec 01; 3(2):75-81. PubMed ID: 3243980
    [Abstract] [Full Text] [Related]

  • 8. CA125 and placental alkaline phosphatase as serum tumor markers in epithelial ovarian carcinoma.
    Vergote IB, Abeler VM, Børmer OP, Stigbrand T, Tropé C, Nustad K.
    Tumour Biol; 1992 Dec 01; 13(3):168-74. PubMed ID: 1626181
    [Abstract] [Full Text] [Related]

  • 9. The serum concentrations of TAG-72 antigen measured with CA 72-4 IRMA in patients with ovarian carcinoma. Preliminary data.
    Gadducci A, Ferdeghini M, Ceccarini T, Prontera C, Facchini V, Bianchi R, Fioretti P.
    J Nucl Med Allied Sci; 1989 Dec 01; 33(1):32-6. PubMed ID: 2746365
    [Abstract] [Full Text] [Related]

  • 10. CA 125 assay used in conjunction with CA 15-3 and TAG-72 assays for discrimination between malignant and non-malignant diseases of the ovary.
    Einhorn N, Knapp RC, Bast RC, Zurawski VR.
    Acta Oncol; 1989 Dec 01; 28(5):655-7. PubMed ID: 2590540
    [Abstract] [Full Text] [Related]

  • 11. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
    Koelbl H, Schieder K, Neunteufel W, Bieglmayer C.
    Neoplasma; 1989 Dec 01; 36(4):473-8. PubMed ID: 2770933
    [Abstract] [Full Text] [Related]

  • 12. CA 15-3 as a tumor marker in gynecological malignancies.
    Scambia G, Benedetti Panici P, Baiocchi G, Perrone L, Greggi S, Mancuso S.
    Gynecol Oncol; 1988 Jun 01; 30(2):265-73. PubMed ID: 3163666
    [Abstract] [Full Text] [Related]

  • 13. Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: influence of histological type, grade of differentiation, and clinical stage of disease.
    Tholander B, Taube A, Lindgren A, Sjöberg O, Stendahl U, Tamsen L.
    Gynecol Oncol; 1990 Oct 01; 39(1):26-33. PubMed ID: 2227570
    [Abstract] [Full Text] [Related]

  • 14. Independent expression in serum of three tumour-associated antigens: CA 125, placental alkaline phosphatase and HMFG2 in ovarian carcinoma.
    Ward BG, Cruickshank DJ, Tucker DF, Love S.
    Br J Obstet Gynaecol; 1987 Jul 01; 94(7):696-8. PubMed ID: 2441739
    [Abstract] [Full Text] [Related]

  • 15. Placental alkaline phosphatase (PLAP)/PLAP-like alkaline phosphatase as tumour marker in relation to CA 125 and TPA for ovarian epithelial tumours.
    Stigbrand T, Riklund K, Tholander B, Hirano K, Lalos O, Stendahl U.
    Eur J Gynaecol Oncol; 1990 Jul 01; 11(5):351-60. PubMed ID: 2097151
    [Abstract] [Full Text] [Related]

  • 16. The role of tumour markers in ovarian cancer.
    Gargano G, Correale M, Abbate I, Falco G, De Frenza N, Lorusso V, De Lena M, De Leonardis A.
    Clin Exp Obstet Gynecol; 1990 Jul 01; 17(1):23-9. PubMed ID: 2194706
    [Abstract] [Full Text] [Related]

  • 17. The value of the human milk fat globule membrane antigen HMFG2 in epithelial ovarian cancer monitoring: comparison with CA125.
    Fisken J, Roulston JE, Sturgeon C, Badley RA, Jönrup I, Aspinall L, Leonard RC.
    Br J Cancer; 1993 May 01; 67(5):1065-70. PubMed ID: 8494699
    [Abstract] [Full Text] [Related]

  • 18. Multi-parameter flow cytometric quantitation of the expression of the tumor-associated antigen SM3 in normal and neoplastic ovarian tissues. A comparison with HMFG1 and HMFG2.
    van Dam PA, Lowe DG, Watson JV, Jobling TW, Chard T, Shepherd JH.
    Cancer; 1991 Jul 01; 68(1):169-77. PubMed ID: 2049739
    [Abstract] [Full Text] [Related]

  • 19. Pre-operative discrimination between benign and malignant ovarian tumors using a combination of CA125 and CA15.3 serum assays.
    Yedema C, Massuger L, Hilgers J, Servaas J, Poels L, Thomas C, Kenemans P.
    Int J Cancer Suppl; 1988 Jul 01; 3():61-7. PubMed ID: 3209301
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.